Curio Wealth’s Citius Pharmaceuticals CTXR Stock Holding History

Curio Wealth’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.8K	Hold	2,000	–	–	﹤0.01%	324
2025 Q4	$1.6K	Buy	+2,000	New	+$2.5K	﹤0.01%	348

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Curio Wealth's CTXR Position: Q1 2026 in Review

Curio Wealth held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 2,000 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #324.

Curio Wealth first reported a position in CTXR in Q4 2025 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

Curio Wealth held 2,000 shares of Citius Pharmaceuticals worth $1.8K as of Q1 2026.
Curio Wealth left its Citius Pharmaceuticals share count unchanged in Q1 2026.
Citius Pharmaceuticals made up ﹤0.01% of Curio Wealth's portfolio in Q1 2026, its #324 holding.
Curio Wealth first reported a position in Citius Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Curio Wealth's 13F filing for Q1 2026, filed 12 May 2026.